

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Note:** This report is intended for use by a medical professional. Please discuss any adjustments to your medication with your treating provider.

## Drug Summary

### (Cancer) Antiemetics

|                               | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|-------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Ondansetron</b> (Zofran®)  | ✓                  |                  |                       |                |
| <b>Tropisetron</b> (Novaban®) | ✓                  |                  |                       |                |

### (Cancer) Antifungals

|                              | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Voriconazole</b> (Vfend®) |                    |                  | ⚠                     |                |

### (Cancer) Antineoplastics

|   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---|--------------------|------------------|-----------------------|----------------|
| <b>Belinostat</b> (Beleodaq®)                 | ✓                  |                  |                       |                |
| <b>Gefitinib</b> (Iressa®)                    | ✓                  |                  |                       |                |
| <b>Irinotecan</b> (Camptosar®, Onivyde®)      |                    | ⚠                |                       |                |
| <b>Mercaptopurine</b> (Purixan®)              | ✓                  |                  |                       |                |
| <b>Sacituzumab govitecan-hziy</b> (Trodelyv®) | ✓                  |                  |                       |                |
| <b>Tamoxifen</b> (Soltamox®)                  |                    |                  | ⚠                     |                |
| <b>Thioguanine</b> (Tabloid®)                 | ✓                  |                  |                       |                |

### (Cancer) Antivirals

|                              | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Atazanavir</b> (Reyataz®) | ✓                  |                  |                       |                |

### (Cancer) Fluoropyrimidines

|   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---|--------------------|------------------|-----------------------|----------------|
| <b>Capecitabine</b> (Xeloda®)           | ✓                  |                  |                       |                |
| <b>Fluorouracil</b> (Efudex®, Adrucil®) | ✓                  |                  |                       |                |
| <b>Tegafur</b> (Teysono®)               | ✓                  |                  |                       |                |

### (Cancer) Immunosuppressants

|  | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|--|--------------------|------------------|-----------------------|----------------|
| <b>Azathioprine</b> (Imuran®, Azasan®) | ✓                  |                  |                       |                |
| <b>Tacrolimus</b> (Prograf®)           | ✓                  |                  |                       |                |

### (Cancer) Uric Acid Inhibitors

|  | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|--|--------------------|------------------|-----------------------|----------------|
| <b>Allopurinol</b> (Zyloprim®, AlopriM®) | ✓                  |                  |                       |                |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## (Cardiovascular) Antiarrhythmics

|                                   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|-----------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Flecainide</b> (Tambocor®)     |                    | ⚠️               |                       |                |
| <b>Propafenone</b> (Rhythmol SR®) |                    | ⚠️               |                       |                |

## (Cardiovascular) Anticoagulants

|  | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|--|--------------------|------------------|-----------------------|----------------|
| <b>Warfarin</b> (Coumadin®, Jantoven®) |                    |                  |                       | ?              |

## (Cardiovascular) Antiplatelets

|                              | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Clopidogrel</b> (Plavix®) | ✅                  |                  |                       |                |

## (Cardiovascular) Beta blockers

|  | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|--|--------------------|------------------|-----------------------|----------------|
| <b>Metoprolol</b> (Lopressor®, Toprol XL®) | ✅                  |                  |                       |                |

## (Cardiovascular) Statins

|   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---|--------------------|------------------|-----------------------|----------------|
| <b>Atorvastatin</b> (Lipitor®, Atorvaliq)         | ✅                  |                  |                       |                |
| <b>Fluvastatin</b> (Lescol XL®)                   | ✅                  |                  |                       |                |
| <b>Lovastatin</b> (Mevacor®, Altoprev®)           | ✅                  |                  |                       |                |
| <b>Pitavastatin</b> (Livalo®, Zypitamag®)         | ✅                  |                  |                       |                |
| <b>Pravastatin</b> (Pravachol®)                   | ✅                  |                  |                       |                |
| <b>Rosuvastatin</b> (Crestor®, Ezallor Sprinkle®) | ✅                  |                  |                       |                |
| <b>Simvastatin</b> (Zocor®, FloLipid®)            | ✅                  |                  |                       |                |

## (Mental Health) Anticonvulsants

|   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---|--------------------|------------------|-----------------------|----------------|
| <b>Brivaracetam</b> (Briviact®)         | ✅                  |                  |                       |                |
| <b>Carbamazepine</b> (Tegretol®)        | ✅                  |                  |                       |                |
| <b>Fosphenytoin</b> (Cerebyx®)          | ✅                  |                  |                       |                |
| <b>Lamotrigine</b> (Lamictal®)          | ✅                  |                  |                       |                |
| <b>Oxcarbazepine</b> (Trileptal®)       | ✅                  |                  |                       |                |
| <b>Phenytoin</b> (Dilantin®, Phenytek®) | ✅                  |                  |                       |                |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## (Mental Health) Antidepressants

|                                   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|-----------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Amitriptyline</b> (Elavil®)    |                    |                  | ⚠                     |                |
| <b>Citalopram</b> (Celexa®)       |                    | ⚠                |                       |                |
| <b>Clomipramine</b> (Anafranil®)  |                    |                  | ⚠                     |                |
| <b>Desipramine</b> (Norpramin®)   |                    | ⚠                |                       |                |
| <b>Doxepin</b> (Sinequan®)        |                    |                  | ⚠                     |                |
| <b>Escitalopram</b> (Lexapro®)    |                    | ⚠                |                       |                |
| <b>Fluvoxamine</b> (Luvox®)       | ✅                  |                  |                       |                |
| <b>Imipramine</b> (Tofranil®)     |                    |                  | ⚠                     |                |
| <b>Nortriptyline</b> (Pamelor®)   |                    | ⚠                |                       |                |
| <b>Paroxetine</b> (Paxil®)        |                    | ⚠                |                       |                |
| <b>Sertraline</b> (Zoloft®)       | ✅                  |                  |                       |                |
| <b>Trimipramine</b> (Surmontil®)  |                    |                  | ⚠                     |                |
| <b>Venlafaxine</b> (Effexor®)     | ✅                  |                  |                       |                |
| <b>Vortioxetine</b> (Trintellix®) | ✅                  |                  |                       |                |

## (Mental Health) Antipsychotics

|                                  | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|----------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Aripiprazole</b> (Abilify®)   | ✅                  |                  |                       |                |
| <b>Brexipiprazole</b> (Rexulti®) | ✅                  |                  |                       |                |
| <b>Clozapine</b> (Clozaril®)     | ✅                  |                  |                       |                |
| <b>Haloperidol</b> (Haldol®)     | ✅                  |                  |                       |                |
| <b>Iloperidone</b> (Fanapt®)     | ✅                  |                  |                       |                |
| <b>Pimozide</b> (Orap®)          |                    | ⚠                |                       |                |
| <b>Quetiapine</b> (Seroquel®)    | ✅                  |                  |                       |                |
| <b>Risperidone</b> (Risperdal®)  | ✅                  |                  |                       |                |
| <b>Thioridazine</b> (Mellaril®)  | ✅                  |                  |                       |                |

## (Mental Health) Anxiolytics

|                         | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|-------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Clobazam</b> (Onfi®) | ✅                  |                  |                       |                |

## (Mental Health) Non-stimulants

|                                 | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---------------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Atomoxetine</b> (Strattera®) |                    | ⚠                |                       |                |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

| (Mental Health) Opioids & related medications | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---|--------------------|------------------|-----------------------|----------------|
|---|--------------------|------------------|-----------------------|----------------|

|                               |   |  |  |  |
|-------------------------------|---|--|--|--|
| <b>Lofexidine</b> (Lucemyra®) | ✓ |  |  |  |
|-------------------------------|---|--|--|--|

| (Mental Health) Stimulants | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|----------------------------|--------------------|------------------|-----------------------|----------------|
|----------------------------|--------------------|------------------|-----------------------|----------------|

|                                |   |  |  |  |
|--------------------------------|---|--|--|--|
| <b>Amphetamine</b> (Adderall®) | ✓ |  |  |  |
|--------------------------------|---|--|--|--|

| (Mental Health) Other | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|-----------------------|--------------------|------------------|-----------------------|----------------|
|-----------------------|--------------------|------------------|-----------------------|----------------|

|                                    |   |  |  |  |
|------------------------------------|---|--|--|--|
| <b>Deutetrabenazine</b> (Austedo®) | ✓ |  |  |  |
| <b>Fiibanserin</b> (Addyi®)        | ✓ |  |  |  |
| <b>Valbenazine</b> (Ingrezza®)     | ✓ |  |  |  |

| (Pain) NSAIDs | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---------------|--------------------|------------------|-----------------------|----------------|
|---------------|--------------------|------------------|-----------------------|----------------|

|                                       |   |  |  |  |
|---------------------------------------|---|--|--|--|
| <b>Celecoxib</b> (CeleBREX®, Elyxyb®) | ✓ |  |  |  |
| <b>Flurbiprofen</b> (Ansaid®)         | ✓ |  |  |  |
| <b>Ibuprofen</b> (Advil®, Motrin®)    | ✓ |  |  |  |
| <b>Lornoxicam</b> (Xefo®)             | ✓ |  |  |  |
| <b>Meloxicam</b> (Mobic®, Vivlodex®)  | ✓ |  |  |  |
| <b>Piroxicam</b> (Feldene®)           | ✓ |  |  |  |
| <b>Tenoxicam</b> (Mobiflex®)          | ✓ |  |  |  |

| (Pain) Opioids & related medications | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|--------------------------------------|--------------------|------------------|-----------------------|----------------|
|--------------------------------------|--------------------|------------------|-----------------------|----------------|

|   |   |  |  |  |
|---|---|--|--|--|
| <b>Codeine</b>                          | ✓ |  |  |  |
| <b>Hydrocodone</b> (Hycodan®, Vicodin®) | ✓ |  |  |  |
| <b>Oliceridine</b> (Olinvyk®)           | ✓ |  |  |  |
| <b>Tramadol</b> (Ultram®, Conzip®)      | ✓ |  |  |  |

| (PPIs) Proton Pump Inhibitors | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|-------------------------------|--------------------|------------------|-----------------------|----------------|
|-------------------------------|--------------------|------------------|-----------------------|----------------|

|                                    |  |   |  |  |
|------------------------------------|--|---|--|--|
| <b>Dexlansoprazole</b> (Dexilant®) |  | ⚠ |  |  |
| <b>Lansoprazole</b> (Prevacid®)    |  | ⚠ |  |  |
| <b>Omeprazole</b> (Prilosec®)      |  | ⚠ |  |  |
| <b>Pantoprazole</b> (Protonix®)    |  | ⚠ |  |  |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## (Other) Aminoglycoside antibacterials

|   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---|--------------------|------------------|-----------------------|----------------|
| <b>Amikacin</b> (Arikayce®)                     | ✓                  |                  |                       |                |
| <b>Dibekacin</b> (Panimycin®, Dibekacin Meiji®) | ✓                  |                  |                       |                |
| <b>Gentamicin</b> (Garamycin®)                  | ✓                  |                  |                       |                |
| <b>Kanamycin</b> (Kantrex®)                     | ✓                  |                  |                       |                |
| <b>Neomycin</b> (Mycifradin®, Neo-Fradin®)      | ✓                  |                  |                       |                |
| <b>Netilmicin</b> (Netromycin®)                 | ✓                  |                  |                       |                |
| <b>Paromomycin</b> (Humatin®)                   | ✓                  |                  |                       |                |
| <b>Plazomicin</b> (Zemdri®)                     | ✓                  |                  |                       |                |
| <b>Ribostamycin</b> (Vistamycin®)               | ✓                  |                  |                       |                |
| <b>Streptomycin</b>                             | ✓                  |                  |                       |                |
| <b>Tobramycin</b> (Tobrex®)                     | ✓                  |                  |                       |                |

## (Other) Antivirals

|                           | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---------------------------|--------------------|------------------|-----------------------|----------------|
| <b>Abacavir</b> (Ziagen®) | ✓                  |                  |                       |                |

## (Other) Interferons

|   | Normal Interaction | Use with Caution | Consider Alternatives | Impact Unknown |
|---|--------------------|------------------|-----------------------|----------------|
| <b>Peginterferon alfa-2a</b> (Pegasys®)   |                    | ⚠                |                       |                |
| <b>Peginterferon alfa-2b</b> (PegIntron®) |                    | ⚠                |                       |                |

## Legend

| SYMBOL | IMPLICATION   |
|--------|---|
| ⚠      | Major gene-drug interaction, consider different drug              |
| ⚠      | Major gene-drug interaction, consider reduced or increased dose   |
| ✓      | No recommended action   |
| ?      | Impact not determined, consider standard dose and alter as needed |

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Gene Summary

| GENE                           | RESULT              | STATUS                   |
|--------------------------------|---------------------|--------------------------|
| ABCB1, rs1045642               | T/C                 | rs1045642 C carrier      |
| ABCB1, rs1128503               | T/C                 | rs1128503 C carrier      |
| ABCB1, rs2032582               | T/G                 | rs2032582 G carrier      |
| ABCG2, rs2231142               | C/C                 | Normal function          |
| AT1C, rs4673993                | T/C                 | rs4673993 C carrier      |
| COMT, rs4680                   | G/G                 | Variant absent           |
| CYP2C Cluster                  | G/G                 | Variant absent           |
| CYP2C19                        | *1/*17              | Rapid Metabolizer        |
| CYP2C9                         | *1/*1               | Normal Metabolizer       |
| CYP2D6                         | *1/*3               | Intermediate Metabolizer |
| CYP3A4                         | *1/*22              | Intermediate Metabolizer |
| CYP3A5                         | *3/*3               | Poor Metabolizer         |
| CYP4F2                         | *1/*3               | Deficient                |
| DPYD                           | Reference/Reference | Normal Metabolizer       |
| F2, c.*97G>A                   | G/G                 | Variant absent           |
| F5, c.1601G>A(p.Arg534Gln)     | G/G                 | Variant absent           |
| GRK4, rs1024323                | C/T                 | rs1024323 T carrier      |
| HLA-B*15:02                    | ABSENT              | HLA-B: *15:02 negative   |
| HLA-B*57:01                    | ABSENT              | HLA-B: *57:01 negative   |
| IFNL3, rs8099917               | T/G                 | rs8099917 G carrier      |
| IFNL3/IFNL4, rs12979860        | T/T                 | rs12979860 T homozygote  |
| MT-RNR1, rs267606617           | A                   | Variant absent           |
| MT-RNR1, rs267606618           | T                   | Variant absent           |
| MT-RNR1, rs267606619           | C                   | Variant absent           |
| MTHFR, c.1286A>C (p.Glu429Ala) | A/C                 | Detected, heterozygous   |
| MTHFR, c.665C>T (p.Ala222Val)  | C/C                 | Variant absent           |
| NUDT15                         | *1/*1               | Normal Metabolizer       |
| OPRM1, rs1799971               | A/A                 | Variant absent           |
| SLC19A1, rs1051266             | A/G                 | rs1051266 G carrier      |
| SLCO1B1                        | *1/*37              | Normal Function          |
| TPMT                           | *1/*1               | Normal Metabolizer       |
| UGT1A1                         | *1/*80              | Intermediate Metabolizer |
| VKORC1, rs9923231              | C/T (G/A)           | rs9923231 T carrier      |

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Drug Details

### (Cancer) Antiemetics

**Ondansetron** (Zofran®) Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Tropisetron** (Novaban®) Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### (Cancer) Antifungals

**Voriconazole** (Vfend®) Consider alternative medication

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

### (Cancer) Antineoplastics

**Belinostat** (Beleodaq®) Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| UGT1A1 | *1/*80 | Intermediate Metabolizer |

**Gefitinib** (Iressa®) Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Irinotecan** (Camptosar®, Onivyde®) Use caution

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| UGT1A1 | *1/*80 | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Mercaptopurine** (Purixan®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| NUDT15 | *1/*1  | Normal Metabolizer |
| TPMT   | *1/*1  | Normal Metabolizer |

**Sacituzumab govitecan-hziy** (Trodelvy®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| UGT1A1 | *1/*80 | Intermediate Metabolizer |

**Tamoxifen** (Soltamox®)

Consider alternative medication

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Thioguanine** (Tabloid®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| NUDT15 | *1/*1  | Normal Metabolizer |
| TPMT   | *1/*1  | Normal Metabolizer |

## Limited Evidence Drug-Gene Associations

**Pazopanib** (Votrient®)

Limited Evidence

| Gene        | Result | Status                |
|-------------|--------|-----------------------|
| HLA-B*57:01 | ABSENT | HLA-B:*57:01 negative |

## (Cancer) Antivirals

**Atazanavir** (Reyataz®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| UGT1A1 | *1/*80 | Intermediate Metabolizer |

## (Cancer) Fluoropyrimidines

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Capecitabine** (Xeloda®)

Normal response expected

| Gene | Result              | Status             |
|------|---------------------|--------------------|
| DPYD | Reference/Reference | Normal Metabolizer |

**Fluorouracil** (Efudex®, Adrucil®)

Normal response expected

| Gene | Result              | Status             |
|------|---------------------|--------------------|
| DPYD | Reference/Reference | Normal Metabolizer |

**Tegafur** (Teysuno®)

Normal response expected

| Gene | Result              | Status             |
|------|---------------------|--------------------|
| DPYD | Reference/Reference | Normal Metabolizer |

## (Cancer) Immunosuppressants

**Azathioprine** (Imuran®, Azasan®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| NUDT15 | *1/*1  | Normal Metabolizer |
| TPMT   | *1/*1  | Normal Metabolizer |

**Tacrolimus** (Prograf®)

Normal response expected

| Gene   | Result | Status           |
|--------|--------|------------------|
| CYP3A5 | *3/*3  | Poor Metabolizer |

## Limited Evidence Drug-Gene Associations

**Methotrexate** (Rasuvo®, Otrexup®)

Limited Evidence

| Gene                          | Result | Status              |
|-------------------------------|--------|---------------------|
| ATIC, rs4673993               | T/C    | rs4673993 C carrier |
| MTHFR, c.665C>T (p.Ala222Val) | C/C    | Variant absent      |
| SLC19A1, rs1051266            | A/G    | rs1051266 G carrier |

## (Cancer) Platelet-stimulating agents

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Limited Evidence Drug-Gene Associations

**Avatrombopag** (Doptelet®) Limited Evidence

| Gene                        | Result | Status         |
|-----------------------------|--------|----------------|
| F5, c.1601G>A (p.Arg534Gln) | G/G    | Variant absent |

**Eltrombopag** (Promacta®) Limited Evidence

| Gene                        | Result | Status         |
|-----------------------------|--------|----------------|
| F5, c.1601G>A (p.Arg534Gln) | G/G    | Variant absent |

**Lusutrombopag** (Mulpleta®) Limited Evidence

| Gene                        | Result | Status         |
|-----------------------------|--------|----------------|
| F5, c.1601G>A (p.Arg534Gln) | G/G    | Variant absent |

## (Cancer) Uric Acid Inhibitors

**Allopurinol** (Zyloprim®, Aloprim®) Normal response expected

| Gene             | Result | Status          |
|------------------|--------|-----------------|
| ABCG2, rs2231142 | C/C    | Normal function |

## (Cardiovascular) Antiarrhythmics

**Flecainide** (Tambocor®) Use caution

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Propafenone** (Rhythmol SR®) Use caution

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Digoxin (Lanoxin®)

Limited Evidence

| Gene             | Result | Status              |
|------------------|--------|---------------------|
| ABCB1, rs1045642 | T/C    | rs1045642 C carrier |
| ABCB1, rs1128503 | T/C    | rs1128503 C carrier |
| ABCB1, rs2032582 | T/G    | rs2032582 G carrier |

## Quinidine (Quinidex®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## (Cardiovascular) Anticoagulants

### Warfarin (Coumadin®, Jantoven®)

Metabolizer Impact Unknown

| Gene              | Result    | Status              |
|-------------------|-----------|---------------------|
| CYP2C Cluster     | G/G       | Variant absent      |
| CYP2C9            | *1/*1     | Normal Metabolizer  |
| CYP4F2            | *1/*3     | Deficient           |
| VKORC1, rs9923231 | C/T (G/A) | rs9923231 T carrier |

## (Cardiovascular) Antihypertensives

### Limited Evidence Drug-Gene Associations

#### Losartan (Cozaar®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer       |
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## (Cardiovascular) Antiplatelets

### Clopidogrel (Plavix®)

Normal response expected

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

## (Cardiovascular) Beta blockers

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Metoprolol** (Lopressor®, Toprol XL®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

**Atenolol** (Tenormin®)

Limited Evidence

| Gene           | Result | Status              |
|----------------|--------|---------------------|
| GRK4,rs1024323 | C/T    | rs1024323 T carrier |

**Carvedilol** (Coreg®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Nebivolol** (Bystolic®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Propranolol** (Inderal®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Timolol** (Timoptol®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## (Cardiovascular) Statins

**Atorvastatin** (Lipitor®, Atorvaliq)

Normal response expected

| Gene    | Result | Status          |
|---------|--------|-----------------|
| SLCO1B1 | *1/*37 | Normal Function |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Fluvastatin** (Lescol XL<sup>®</sup>)

Normal response expected

| Gene    | Result | Status             |
|---------|--------|--------------------|
| CYP2C9  | *1/*1  | Normal Metabolizer |
| SLCO1B1 | *1/*37 | Normal Function    |

**Lovastatin** (Mevacor<sup>®</sup>, Altoprev<sup>®</sup>)

Normal response expected

| Gene    | Result | Status          |
|---------|--------|-----------------|
| SLCO1B1 | *1/*37 | Normal Function |

**Pitavastatin** (Livalo<sup>®</sup>, Zypitamag<sup>®</sup>)

Normal response expected

| Gene    | Result | Status          |
|---------|--------|-----------------|
| SLCO1B1 | *1/*37 | Normal Function |

**Pravastatin** (Pravachol<sup>®</sup>)

Normal response expected

| Gene    | Result | Status          |
|---------|--------|-----------------|
| SLCO1B1 | *1/*37 | Normal Function |

**Rosuvastatin** (Crestor<sup>®</sup>, Ezallor Sprinkle<sup>®</sup>)

Normal response expected

| Gene             | Result | Status          |
|------------------|--------|-----------------|
| ABCG2, rs2231142 | C/C    | Normal function |
| SLCO1B1          | *1/*37 | Normal Function |

**Simvastatin** (Zocor<sup>®</sup>, FloLipid<sup>®</sup>)

Normal response expected

| Gene    | Result | Status          |
|---------|--------|-----------------|
| SLCO1B1 | *1/*37 | Normal Function |

## (Mental Health) Anticonvulsants

**Brivaracetam** (Briviact<sup>®</sup>)

Normal response expected

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Carbamazepine** (Tegretol®)

Normal response expected

| Gene        | Result | Status                 |
|-------------|--------|------------------------|
| HLA-B*15:02 | ABSENT | HLA-B: *15:02 negative |

**Fosphenytoin** (Cerebyx®)

Normal response expected

| Gene        | Result | Status                 |
|-------------|--------|------------------------|
| CYP2C9      | *1/*1  | Normal Metabolizer     |
| HLA-B*15:02 | ABSENT | HLA-B: *15:02 negative |

**Lamotrigine** (Lamictal®)

Normal response expected

| Gene        | Result | Status                 |
|-------------|--------|------------------------|
| HLA-B*15:02 | ABSENT | HLA-B: *15:02 negative |

**Oxcarbazepine** (Trileptal®)

Normal response expected

| Gene        | Result | Status                 |
|-------------|--------|------------------------|
| HLA-B*15:02 | ABSENT | HLA-B: *15:02 negative |

**Phenytoin** (Dilantin®, Phenytek®)

Normal response expected

| Gene        | Result | Status                 |
|-------------|--------|------------------------|
| CYP2C9      | *1/*1  | Normal Metabolizer     |
| HLA-B*15:02 | ABSENT | HLA-B: *15:02 negative |

## (Mental Health) Antidepressants

**Amitriptyline** (Elavil®)

Consider alternative medication

| Gene    | Result | Status                   |
|---------|--------|--------------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer        |
| CYP2D6  | *1/*3  | Intermediate Metabolizer |

**Citalopram** (Celexa®)

Use caution

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Clomipramine** (Anafranil®)

Consider alternative medication

| Gene    | Result | Status                   |
|---------|--------|--------------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer        |
| CYP2D6  | *1/*3  | Intermediate Metabolizer |

**Desipramine** (Norpramin®)

Decrease dose

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Doxepin** (Sinequan®)

Consider alternative medication

| Gene    | Result | Status                   |
|---------|--------|--------------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer        |
| CYP2D6  | *1/*3  | Intermediate Metabolizer |

**Escitalopram** (Lexapro®)

Use caution

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

**Fluvoxamine** (Luvox®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Imipramine** (Tofranil®)

Consider alternative medication

| Gene    | Result | Status                   |
|---------|--------|--------------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer        |
| CYP2D6  | *1/*3  | Intermediate Metabolizer |

**Nortriptyline** (Pamelor®)

Decrease dose

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Paroxetine (Paxil®)

Decrease dose

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Sertraline (Zoloft®)

Normal response expected

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

## Trimipramine (Surmontil®)

Consider alternative medication

| Gene    | Result | Status                   |
|---------|--------|--------------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer        |
| CYP2D6  | *1/*3  | Intermediate Metabolizer |

## Venlafaxine (Effexor®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Vortioxetine (Trintellix®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Limited Evidence Drug-Gene Associations

#### Amoxapine (Asendin®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

#### Bupropion (Wellbutrin®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Desvenlafaxine (Pristiq®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Duloxetine (Cymbalta®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Fluoxetine (Prozac®)

Limited Evidence

| Gene    | Result | Status                   |
|---------|--------|--------------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer        |
| CYP2D6  | *1/*3  | Intermediate Metabolizer |

## Levomilnacipran (Fetzima®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## Maprotiline (Ludiomil®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Mirtazapine (Remeron®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## Protriptyline (Vivactil®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Trazodone (Desyrel®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## Vilazodone (Viibryd®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## (Mental Health) Antipsychotics

### Aripiprazole (Abilify®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Brexpiprazole (Rexulti®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Clozapine (Clozaril®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Haloperidol (Haldol®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Iloperidone (Fanapt®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Pimozide** (Orap®)

Decrease dose

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Quetiapine** (Seroquel®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

**Risperidone** (Risperdal®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Thioridazine** (Mellaril®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

**Aripiprazole** (Abilify®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

**Brexpiprazole** (Rexulti®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

**Cariprazine** (Vraylar®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Clozapine (Clozaril®)

Limited Evidence

| Gene                           | Result | Status                   |
|--------------------------------|--------|--------------------------|
| CYP3A4                         | *1/*22 | Intermediate Metabolizer |
| MTHFR, c.1286A>C (p.Glu429Ala) | A/C    | Detected, heterozygous   |

## Iloperidone (Fanapt®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## Lurasidone (Latuda®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## Olanzapine (Zyprexa®)

Limited Evidence

| Gene                           | Result | Status                   |
|--------------------------------|--------|--------------------------|
| CYP2D6                         | *1/*3  | Intermediate Metabolizer |
| MTHFR, c.1286A>C (p.Glu429Ala) | A/C    | Detected, heterozygous   |

## Paliperidone (Invega®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Perphenazine (Trilafon®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Pimozide (Orap®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Ziprasidone** (Geodon®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## (Mental Health) Anxiolytics

**Clobazam** (Onfi®)

Normal response expected

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

### Limited Evidence Drug-Gene Associations

**Alprazolam** (Xanax®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

**Buspirone** (BuSpar®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

**Clonazepam** (Klonopin®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

**Diazepam** (Valium®)

Limited Evidence

| Gene    | Result | Status                   |
|---------|--------|--------------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer        |
| CYP3A4  | *1/*22 | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Triazolam (Halcion®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## (Mental Health) Non-stimulants

### Atomoxetine (Strattera®)

Use caution

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

### Viloxazine (Qelbree®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## (Mental Health) Opioids & related medications

### Lofexidine (Lucemyra®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

### Naloxone (Evzio®, Narcan®)

Limited Evidence

| Gene             | Result | Status         |
|------------------|--------|----------------|
| COMT, rs4680     | G/G    | Variant absent |
| OPRM1, rs1799971 | A/A    | Variant absent |

## (Mental Health) Stimulants

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Amphetamine** (Adderall®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

**Methylphenidate** (Ritalin®, Concerta®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## (Mental Health) Other

**Deutetrabenzazine** (Austedo®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

**Flibanserin** (Addyi®)

Normal response expected

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

**Valbenazine** (Ingrezza®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

**Eszopiclone** (Lunesta®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Flibanserin (Addyi®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer       |
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Lithium (Lithobid®)

Limited Evidence

| Gene            | Result | Status              |
|-----------------|--------|---------------------|
| ABCB1,rs2032582 | T/G    | rs2032582 G carrier |

## Zolpidem (Ambien®)

Limited Evidence

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP3A4 | *1/*22 | Intermediate Metabolizer |

## (Pain) NSAIDs

### Celecoxib (CeleBREX®, Elyxyb®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

### Flurbiprofen (Ansaid®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

### Ibuprofen (Advil®, Motrin®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

### Lornoxicam (Xefo®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Meloxicam** (Mobic®, Vivlodex®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

**Piroxicam** (Feldene®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

**Tenoxicam** (Mobiflex®)

Normal response expected

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

## Limited Evidence Drug-Gene Associations

**Aceclofenac** (Preservex®)

Limited Evidence

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

**Diclofenac** (Zipsor®, Zorvolex®)

Limited Evidence

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

**Indomethacin** (Indocin®, Tivorbex®)

Limited Evidence

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

**Lumiracoxib** (Prexige®)

Limited Evidence

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Metamizole

Limited Evidence

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

## Nabumetone (Relafen®)

Limited Evidence

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

## Naproxen (Aleve®, Naprelan®)

Limited Evidence

| Gene   | Result | Status             |
|--------|--------|--------------------|
| CYP2C9 | *1/*1  | Normal Metabolizer |

## (Pain) Opioids & related medications

### Codeine

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Hydrocodone (Hycodan®, Vicodin®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Oliceridine (Olinvyk®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

### Tramadol (Ultram®, Conzip®)

Normal response expected

| Gene   | Result | Status                   |
|--------|--------|--------------------------|
| CYP2D6 | *1/*3  | Intermediate Metabolizer |

## Limited Evidence Drug-Gene Associations

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## **Alfentanil** (Alfenta®)

Limited Evidence

| Gene             | Result | Status         |
|------------------|--------|----------------|
| OPRM1, rs1799971 | A/A    | Variant absent |

## **Buprenorphine** (Buprenex®, Butrans®, Probuphine®)

Limited Evidence

| Gene             | Result | Status                   |
|------------------|--------|--------------------------|
| COMT, rs4680     | G/G    | Variant absent           |
| CYP3A4           | *1/*22 | Intermediate Metabolizer |
| OPRM1, rs1799971 | A/A    | Variant absent           |

## **Fentanyl**

Limited Evidence

| Gene             | Result | Status                   |
|------------------|--------|--------------------------|
| COMT, rs4680     | G/G    | Variant absent           |
| CYP3A4           | *1/*22 | Intermediate Metabolizer |
| OPRM1, rs1799971 | A/A    | Variant absent           |

## **Hydromorphone** (Dilaudid®)

Limited Evidence

| Gene             | Result | Status         |
|------------------|--------|----------------|
| COMT, rs4680     | G/G    | Variant absent |
| OPRM1, rs1799971 | A/A    | Variant absent |

## **Morphine**

Limited Evidence

| Gene             | Result | Status         |
|------------------|--------|----------------|
| COMT, rs4680     | G/G    | Variant absent |
| OPRM1, rs1799971 | A/A    | Variant absent |

## **Oxycodone** (Oxycontin®)

Limited Evidence

| Gene             | Result | Status                   |
|------------------|--------|--------------------------|
| COMT, rs4680     | G/G    | Variant absent           |
| CYP2D6           | *1/*3  | Intermediate Metabolizer |
| OPRM1, rs1799971 | A/A    | Variant absent           |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## Sufentanil (Sufenta®)

Limited Evidence

| Gene             | Result | Status                   |
|------------------|--------|--------------------------|
| COMT, rs4680     | G/G    | Variant absent           |
| CYP3A4           | *1/*22 | Intermediate Metabolizer |
| CYP3A5           | *3/*3  | Poor Metabolizer         |
| OPRM1, rs1799971 | A/A    | Variant absent           |

## (Pain) Tranquilizers

### Limited Evidence Drug-Gene Associations

## Carisoprodol (Soma®)

Limited Evidence

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

## (PPIs) Proton Pump Inhibitors

## Dexlansoprazole (Dexilant®)

Use caution

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

## Lansoprazole (Prevacid®)

Use caution

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

## Omeprazole (Prilosec®)

Use caution

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

## Pantoprazole (Protonix®)

Use caution

| Gene    | Result | Status            |
|---------|--------|-------------------|
| CYP2C19 | *1/*17 | Rapid Metabolizer |

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## (Other) Aminoglycoside antibacterials

**Amikacin** (Arikayce®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Dibekacin** (Panimycin®, Dibekacin Meiji®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Gentamicin** (Garamycin®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Kanamycin** (Kantrex®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Neomycin** (Mycifradin®, Neo-Fradin®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

**Netilmicin** (Netromycin®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Paromomycin** (Humatin®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Plazomicin** (Zemdri®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Ribostamycin** (Vistamycin®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Streptomycin**

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

**Tobramycin** (Tobrex®)

Normal response expected

| Gene                 | Result | Status         |
|----------------------|--------|----------------|
| MT-RNR1, rs267606617 | A      | Variant absent |
| MT-RNR1, rs267606618 | T      | Variant absent |
| MT-RNR1, rs267606619 | C      | Variant absent |

# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## (Other) Antivirals

**Abacavir** (Ziagen®)

Normal response expected

| Gene        | Result | Status                 |
|-------------|--------|------------------------|
| HLA-B*57:01 | ABSENT | HLA-B: *57:01 negative |

## (Other) Contraceptives

### Limited Evidence Drug-Gene Associations

**Hormonal contraceptives**

Limited Evidence

| Gene                        | Result | Status         |
|-----------------------------|--------|----------------|
| F2, c.*97G>A                | G/G    | Variant absent |
| F5, c.1601G>A (p.Arg534Gln) | G/G    | Variant absent |

## (Other) Interferons

**Peginterferon alfa-2a** (Pegasys®)

Use caution

| Gene                    | Result | Status                  |
|-------------------------|--------|-------------------------|
| IFNL3/IFNL4, rs12979860 | T/T    | rs12979860 T homozygote |

**Peginterferon alfa-2b** (PegIntron®)

Use caution

| Gene                    | Result | Status                  |
|-------------------------|--------|-------------------------|
| IFNL3/IFNL4, rs12979860 | T/T    | rs12979860 T homozygote |

### Limited Evidence Drug-Gene Associations

**Peginterferon alfa-2a** (Pegasys®)

Limited Evidence

| Gene             | Result | Status              |
|------------------|--------|---------------------|
| IFNL3, rs8099917 | T/G    | rs8099917 G carrier |

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

## ? Peginterferon alfa-2b (PegIntron®)

Limited Evidence

| Gene             | Result | Status              |
|------------------|--------|---------------------|
| IFNL3, rs8099917 | T/G    | rs8099917 G carrier |

## Methods and Limitations

Data were generated from extracted DNA using the validated Helix Exome+ assay by the Helix clinical laboratory. The Exome+ assay is based on target enrichment followed by next generation sequencing using paired end reads on an Illumina DNA sequencing system. Star alleles were determined using a proprietary algorithm which performs variant calling and then determines star allele solutions based on a combination of defining SNPs and exon-level copy number.

Metabolizer status was determined based on star allele solutions according to CPIC guidelines, with the following exceptions: (1) metabolizer status was set as Indeterminate if a novel nonsense or truncating novel mutation was observed within the gene, (2) metabolizer status was set as Indeterminate if the combination of defining SNPs and copy number suggested a novel star allele solution, and (3) if more than two copies of a gene were detected then metabolizer status was set as Indeterminate. Drug/gene considerations were limited to guidelines published by FDA, CPIC, or PharmGKB.

Phasing could not be performed for genotypes, and therefore in some cases the star allele solution could not be disambiguated between two or more equally likely possibilities. In these cases, if the metabolizer status was the same regardless of possible star allele solutions, the more common star allele solution was provided along with the metabolizer status. If the metabolizer status was different for the equally-likely star allele solutions, the star alleles were reported as Unknown and the metabolizer status was considered Indeterminate.

All samples were sequenced and interpreted in Helix's CLIA-certified (#05D2117342) and CAP-accredited (#9382893) laboratory in San Diego, California. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

The reportable range includes the following results:

ABCB1: rs2032582, rs1128503, rs1045642; ABCG2: rs2231142; ATIC: rs4673993; COMT: rs4680; CYP2C cluster: rs12777823; CYP2C9: \*1-\*61; CYP2C19: \*1-\*19, \*22-\*26, \*28-\*39; CYP2D6: \*1-\*15, \*4N, \*17-\*65, \*68-\*75, \*81, \*83-\*114; CYP3A4: \*1-\*24, \*26, \*28-\*38; CYP3A5: \*1, \*3, \*6-\*9; CYP4F2: \*1, \*3; DPYD: \*1, \*2A, \*3, \*4, \*6-\*8, \*9B, \*10-\*13, HapB3, rs150036960, rs72549310, rs80081766, rs150385342, rs141462178, rs200562975, rs2297595, rs139834141, rs6670886, rs115232898, rs72549308, rs72549307, rs45589337, rs146356975, rs150437414, rs145112791, rs201018345, rs183385770, rs143154602, rs72549305, rs75017182, rs140602333, rs143815742, rs61622928, rs200064537, rs764666241, rs142512579, rs186169810, rs72975710, rs144395748, rs57918000, rs199549923, rs72549304, rs111858276, rs138391898, rs148994843, rs190951787, rs142619737, rs201615754, rs59086055, rs138616379, rs145773863, rs147601618, rs17376848, rs3918289, rs55971861, rs138545885, rs137999090, rs145548112, rs146529561, rs60511679, rs112766203, rs56005131, rs199634007, rs200687447, rs60139309, rs201035051, rs55674432, rs147545709, rs67376798, rs141044036, rs145529148, rs72547602, rs72547601, rs202144771, rs139459586, rs140114515, rs148799944, rs114096998; F2: c.\*97G>A; F5: c.1601G>A (p.Arg534Gln); GRK4: rs1024323; HLA-B\*15:02, \*57:01; IFNL3: rs8099917; IFNL3/IFNL4: rs12979860; MT-RNR1: rs267606617, rs267606618, rs267606619; MTHFR: c.1286A>C (p.Glu429Ala), c.665C>T (p.Ala222Val); NUDT15: \*1-\*20; OPRM1: rs1799971; SLC19A1: rs1051266; SLCO1B1: \*1-\*16, \*19, \*20, \*23-\*34, \*36-\*44, \*47-\*49; TPMT: \*1, \*2, \*3A, \*3B, \*3C, \*4-\*44; UGT1A1: \*1, \*6, \*27, \*80; VKORC1: rs9923231. Sensitivity may be reduced for the CYP2D6\*13 allele. UGT1A1\*80 is used as a proxy for UGT1A1\*28 and therefore treated as decreased function.

Results are based on:

Abacavir, HLA-B\*57:01 (FDA Section 1, CPIC A); Allopurinol, ABCG2 (PGKB 1A); Amikacin, MT-RNR1 (CPIC A); Amitriptyline, CYP2C19, CYP2D6 (CPIC A); Amphetamine, CYP2D6 (FDA Section 1); Aripiprazole, CYP2D6 (FDA Section 1); Atazanavir, UGT1A1 (CPIC A); Atomoxetine, CYP2D6 (FDA Section 1); Atorvastatin, SLCO1B1 (CPIC A); Azathioprine, NUDT15, TPMT (FDA Section 1, CPIC A); Belinostat, UGT1A1 (FDA Section 1); Brexpiprazole, CYP2D6 (FDA Section 1); Brivaracetam, CYP2C19 (FDA Section 1); Capecitabine, DPYD (FDA Section 1, CPIC A); Carbamazepine, HLA-B\*15:02 (FDA Section 1; CPIC A); Celecoxib, CYP2C9 (FDA Section 1); Citalopram, CYP2C19 (FDA Section 1; CPIC A); Clobazam, CYP2C19 (FDA Section 1); Clomipramine, CYP2C19, CYP2D6 (PGKB 1A); Clopidogrel, CYP2C19 (FDA Section 1); Clozapine, CYP2D6 (FDA Section 1); Codeine, CYP2D6 (FDA Section 1, CPIC A); Desipramine, CYP2D6 (PGKB 1A); Deutetrabenazine, CYP2D6 (FDA section 1); Dexlansoprazole, CYP2C19 (PGKB 1A); Dibekacin, MT-RNR1, (CPIC A); Doxepin, CYP2C19, CYP2D6 (PGKB 1A); Escitalopram, CYP2C19 (CPIC A); Flecainide, CYP2D6 (PGKB 1A); Flibanserin, CYP2C19 (FDA Section 1); Fluorouracil, DPYD (FDA Section 1, CPIC A); Flurbiprofen, CYP2C9 (FDA Section 1); Fluvastatin, CYP2C9, SLCO1B1 (CPIC A); Fluvoxamine, CYP2D6 (PGKB 1A); Fosphenytoin, CYP2C9, HLA-B\*15:02 (FDA Section 1, CPIC A); Gefitinib, CYP2D6 (FDA Section 1); Gentamicin, MT-RNR1 (CPIC A); Haloperidol, CYP2D6 (PGKB 1A); Hydrocodone, CYP2D6 (PGKB 1A); Ibuprofen, CYP2C9 (PGKB 1A); Iloperidone, CYP2D6 (FDA Section 1); Imipramine, CYP2C19, CYP2D6 (PGKB 1A); Irinotecan, UGT1A1 (FDA Section 1); Kanamycin, MT-RNR1 (CPIC A); Lamotrigine, HLA-B\*15:02 (PGKB 1A; DPWG); Lansoprazole, CYP2C19 (PGKB 1A; CPIC A); Lofexidine, CYP2D6 (FDA section 1); Lornoxicam, CYP2C9 (PGKB 1A); Lovastatin, SLCO1B1 (CPIC A); Meloxicam, CYP2C9



# Helix Comprehensive Pharmacogenomics (PGx) Panel

Patient Name: Jane Doe  
Date of Birth: 1990-01-01

Patient ID: XXXXXX  
Helix ID: XXXXXX

Provider Name: Client Client  
Collection Date: 2026-01-31

Order Date: 2026-02-02  
Report Date: 2026-02-03

(FDA Section 1); Mercaptopurine, NUDT15, TPMT (FDA Section 1, CPIC A); Metoprolol, CYP2D6 (PGKB 1A); Neomycin, MT-RNR1, (CPIC A); Netilmicin, MT-RNR1, (CPIC A); Nortriptyline, CYP2D6 (CPIC A); Oliceridine, CYP2D6 (FDA Section 1); Omeprazole, CYP2C19 (PGKB 1A; CPIC A); Ondansetron, CYP2D6 (CPIC A); Oxcarbazepine, HLA-B\*15:02 (CPIC A); Pantoprazole, CYP2C19 (FDA Section 1; CPIC A); Paromomycin, MT-RNR1, (CPIC A); Paroxetine, CYP2D6 (CPIC A; Phenoconverter); Peginterferon alfa-2a, IFNL3 / IFNL4 (CPIC A); Peginterferon alfa-2b, IFNL3 / IFNL4 (CPIC A); Phenytoin, CYP2C9, HLA-B\*15:02 (FDA Section 1, CPIC A); Pimozide, CYP2D6 (FDA section 1); Piroxicam, CYP2C9 (FDA Section 1); Pitavastatin, SLCO1B1 (CPIC A); Plazomicin, MT-RNR1 (CPIC A); Pravastatin, SLCO1B1 (CPIC A); Propafenone, CYP2D6 (FDA Section 1); Quetiapine, CYP3A4 (PGKB 1A; DPWG; FDA label); Ribostamycin, MT-RNR1, (CPIC A); Risperidone, CYP2D6 (PGKB 1A; DPWG); Rosuvastatin, ABCG2, SLCO1B1 (CPIC A); Sacituzumab govitecan-hziy, UGT1A1 (FDA Section 1); Sertraline, CYP2C19 (CPIC A); Simvastatin, SLCO1B1 (CPIC A); Streptomycin, MT-RNR1 (CPIC A); Tacrolimus, CYP3A5 (FDA Section 1); Tamoxifen, CYP2D6 (CPIC A); Tegafur, DPYD (PGKB 1A); Tenoxicam, CYP2C9 (PGKB 1A); Thioguanine, NUDT15, TPMT (FDA Section 1, CPIC A); Thioridazine, CYP2D6 (FDA section 1); Tobramycin, MT-RNR1 (CPIC A); Tramadol, CYP2D6 (FDA Section 1, CPIC A); Trimipramine, CYP2C19, CYP2D6 (PGKB 1A); Tropisetron, CYP2D6 (CPIC A); Valbenazine, CYP2D6 (FDA section 1); Venlafaxine, CYP2D6 (FDA section 1); Voriconazole, CYP2C19 (FDA Section 1, CPIC A); Vortioxetine, CYP2D6 (FDA section 1; CPIC A); Warfarin, CYP2C cluster (PGKB 1A); Warfarin, CYP2C9, CYP4F2, VKORC1 (FDA Section 1, CPIC A).

## Disclaimer

The interpretations and drug considerations provided by Helix are intended solely for use by a medical professional and do not constitute medical advice by Helix. All treatment decisions and diagnoses remain the full responsibility of the treating provider. Results included in this report are based on the guidelines published by the FDA and CPIC, and do not account for other factors that may impact drug response, such as environment, medical conditions, drug-drug interactions, or additional genetic variants. Helix is not responsible or liable for any errors, omissions, or ambiguities in the interpretation or use of the results of this report. Administration of any medication listed in this report requires careful therapeutic monitoring regardless of the drug considerations outlined in this report. All dates and times displayed are Pacific Time and may vary from the dates and times for Collection, Order and Report for the providers/patients.

## Result Notations

<https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations>  
<https://cpicpgx.org/guidelines>  
<https://www.pharmgkb.org/guidelineAnnotations>

## Report Signed By

Kenneth David Becker, PhD, HCLD, CQ, CGMBS

## Helix's Sequence Once, Query Often® Model

When your provider orders a genetic test through Helix, we use our proprietary Sequence Once, Query Often® model to perform whole exome sequencing and analyze the specific genes related to the test. Helix securely stores your whole exome for future clinical use. With your permission, this allows your health care providers to order future medically necessary genetic tests from Helix without needing another sample. Instead, these tests are conducted through digital analysis of your stored genetic information.

To learn more about how Helix protects the privacy and security of your genetic information and learn more about your rights, please visit <https://www.helix.com/privacy-and-policy-highlights>.